

7th Canadian Kidney Cancer Forum

Canadian Kidney Cancer Forum

FINAL PROGRAM

February 4-6, 2016

Westin Bristol Hotel, Toronto, ON

7th Canadian Kidney Cancer Forum

Objectives for Forum 2016

The primary meeting objectives are to:

- Increase knowledge of recent developments in the management of renal cell carcinoma
- Discuss and stimulate new research in kidney cancer nationally
- Develop research questions pertaining to the identified Top Ten Uncertainties in Kidney Cancer (CKCF2015) that can be addressed by Canadian researchers using peer review grant and other support. It is anticipated that research teams will be formed and that they will leave the meeting with project outlines.
- Raise awareness of ongoing research in kidney cancer in Canada
- Foster the ongoing work of the KCRNC initiatives (Genetics, Personalized Medicine, Quality of Care, Survivorship)
- Identify future initiatives and projects for the KCRNC
- Explore ideas to ensure the progress and sustainability of KCRNC

THURSDAY, FEBRUARY 4, 2016

1300 - 1800 Arrival & Registration

1830 - 1930 Buffet Dinner - [Sutton C](#)

SESSION I - [Sutton B](#)

Moderators: J-B Lattouf & Neil Reaume

1930 - 1935 WELCOME

1935 - 2020 *How Are We Going to Pay for This? - The Economic Burden of RCC: Societal vs Individual Viewpoints*
Alice Dragomir/Deb Maskens
Discussant: Neil Reaume

2020 - 2100 *Science Roundtable*
Moderators: Denis Soulières & Fred Pouliot

2100 - 2130 *Management of RCC: How to Use Lessons From the Past*
Bernard Escudier

February 4-6, 2016 • Westin Bristol Hotel, Toronto, ON

7th Canadian Kidney Cancer Forum

2130 - 2300 "Catching Up on the Latest": Networking in the Hospitality Suite - [Suite 1035](#)

FRIDAY, FEBRUARY 5, 2016

0700 - 0800 CKCis (Canadian Kidney Cancer information system) Operations Committee Meeting - [Sutton B](#)
(Site investigators & staff-by invitation only)

0700 - 0800 Buffet Breakfast - [Sutton A](#)

SESSION II - [Sutton B](#)

Moderators: Daniel Heng & Simon Tanguay

0800 - 0830 CKCis (Canadian Kidney Cancer information system) - Project Updates
CKCis Update
Simon Tanguay
Real world outcomes of patients with mRCC using first-line sunitinib or pazopanib
Aly-Khan Lalani

0830 - 0900 New Treatment Algorithms in Metastatic Renal Cell Carcinoma
Eric Jonasch

0900 - 0905 Overview of Priority Setting Research Project
Michael Jewett/Jennifer Jones

0905 - 0935 Top Ten Session I: Non-Clear Cell RCC
Moderator: Steve Pautler

Mechanism-Based Treatment Strategies in Non-Clear Cell RCC
Ramaprasad Srinivasan

0935 - 1005 Top Ten Session 2: Biomarkers
George Yousef/Georg Bjarnason

1005 - 1035 Exhibitor Break - [Sutton A](#)
Poster Viewing

7th Canadian Kidney Cancer Forum

SESSION III - Sutton B

Moderator: Naveen Basappa

- 1035 - 1120 Top Ten Session 3: Immunotherapy
Immunotherapy for Kidney Cancer - Current Status /
Future Prospects
Charles Drake
- 1120 - 1220 Breakout Groups - Topics 1-3 - [Carlyle, Sutton B & C](#)
- 1220 - 1315 Buffet Lunch - [Sutton A](#)
[Poster Viewing](#)
- 1220 - 1315 OZM Investigator's Meeting (by invitation only) - [Sutton C](#)

SESSION IV - Sutton B

Moderators: Lori Wood & Anil Kapoor

- 1315 - 1345 Cytoreductive Nephrectomy - An Update
Axel Bex
- 1345 - 1415 Top Ten Session 4: Patient & Family Support
Jennifer Jones/Christina Canil/Andrew Matthew
- 1415 - 1445 Top Ten Session 5: Decision Making Tools
Moderator: Rod Breau
Dawn Stacey/Pierre Karakiewicz
- 1445 - 1515 Top Ten Session 6: Biopsy
Tony Finelli/Andy Evans
- 1515 - 1545 Exhibitor Break - [Sutton A](#)
[Poster Viewing](#)
- 1545 - 1645 Breakout Groups - Topics 4-6 - [Carlyle, Sutton B & C](#)

7th Canadian Kidney Cancer Forum

SESSION V - Sutton B

Moderator: Raymond Kim

- 1645 - 1730 Delivery of Genetic Care & the Future of Kidney Cancer Genomics
Ramaprasad Srinivasan/Eric Jonasch
- 1900 - 1930 Mix & Mingle - [Sutton Foyer](#)
- 1930 Banquet Dinner "Tribute to a Legend"
- 2130 - 2300 "Catching Up on the Latest": Networking in the Hospitality Suite - [Suite 1035](#)

SATURDAY, FEBRUARY 6, 2016

- 0700 - 0800 Buffet Breakfast - [Sutton A](#)

SESSION VI - Sutton B

Moderators: Georg Bjarnason & Ricardo Rendon

- 0800 - 0830 The Role of Lymph Node Dissection
Axel Bex
- 0830 - 0900 Mechanisms of Resistance to Antiangiogenic Therapy
Eric Jonasch

SESSION VII - Sutton B

Moderators: J-B Lattouf & Neil Reaume

Dragons' Den Part 1 with Dragons Bex, Drake, Jonasch, Srinivasan and Jewett

- 0900 - 0930 Non-Clear Cell RCC
- 0930 - 1000 Biomarkers
- 1000 - 1030 Immunotherapy
- 1030 - 1100 Exhibitor Break - [Sutton A](#)
[Poster Viewing](#)

7th Canadian Kidney Cancer Forum

SESSION VIII - Sutton B

Moderators: Scott North & Alan So

Dragons' Den Part 2 with Dragons Bex, Drake, Jonasch, Srinivasan and Jewett

- 1100 - 1130 Patient & Family Support
- 1130 - 1200 Decision Making Tools
- 1200 - 1230 Biopsy
- 1230 - 1240 Presentation of Dragons' Den Award
Michael Jewett/Anil Kapoor
- 1240 - 1250 Presentation to Sponsors
J-B Lattouf/Neil Reaume
- 1250 - 1300 Next Steps for KCRNC
Anil Kapoor
- 1300 - 1315 Lunch (Boxed lunch provided) - Sutton A

SUPPORTED BY

KCRNC KIDNEY CANCER RESEARCH
NETWORK OF CANADA

RRCRC RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



CIHR IRSC
Canadian Institutes of Health Research | Institut de recherche en santé du Canada



The foundation
of kidney care.
Totalement dévouée
aux soins du rein.

February 4-6, 2016 • Westin Bristol Hotel, Toronto, ON

BIOGRAPHIES



Axel Bex

Dr. Axel Bex is a urologic surgeon at the Netherlands Cancer Institute, Amsterdam, The Netherlands.

Dr. Bex completed his medical studies at the University of Aachen, Germany in 1990 followed by residencies in Surgery and Urology at the University of Essen Medical School, Germany. He was licensed as a urologic surgeon at the Medical Council in Germany in 1996 after which he specialized further in genitourinary oncology. He obtained his PhD from Utrecht University in 2005.

Dr. Bex's main clinical research interest focuses on metastatic renal cell carcinoma and the role of cytoreductive nephrectomy and metastasectomy.

In collaboration with the Department of Immunology, Axel Bex is also investigating factors downregulating the response to immunotherapy with interferon alpha and interleukin-2 in tumor tissue and peripheral blood as one of the few centers that have access to tumor tissue after treatment with biological response modifiers.

Dr. Bex is a member of the European Association of Urology (EAU), the European Organization for Research and Treatment of Cancer (EORTC) and Dutch and German national urological associations. He is a reviewer for European Urology, British Journal of Urology, Urology, Lancet and Lancet Oncology and is also the Co-Chair of the EAU Guideline Panel on Renal Cell Carcinoma.



Alice Dragomir

Dr. Alice Dragomir is assistant professor at the McGill University, Faculty of Medicine, and scientist in health economics and outcomes research at the Research Institute of the McGill University Health Center. Dr. Dragomir is an economist and biostatistician with a master's degree in statistics and a doctoral degree in pharmacoepidemiology and pharmacoeconomics, from the University of Montreal. She has 13 years of experience in academic research. She has been involved in research projects focused on the evaluation of health outcomes and health economics related to different treatment strategies, adherence to treatments, health services utilization and disease modeling in several fields, such as: hypertension, dyslipidemia, cardiovascular diseases, osteoporosis, mental health diseases, and cancers. Her current research is focused on clinical and economic evaluation of different treatments strategies offered to patients with urologic cancers. She has an extended experience in analyzing administrative healthcare databases, such as RAMQ and Med-Echo. Her research represents a valuable tool for decision-makers and clinician leaders when evaluating the clinical and economic impacts of innovative treatments.

BIOGRAPHIES



Charles G. Drake, MD, PhD

Charles Drake received his PhD in Immunology from the National Jewish Center for Immunology, and his MD from the University of Colorado Health Sciences Center. After completing an internal medicine residency on the Osler medicine service at Johns Hopkins, he entered the field of medical oncology. During Dr. Drake's oncology fellowship, he began to investigate the immune response to cancer, developing a unique mouse model to perform studies on specific

immune cell tolerance to tumors. Experiments in this model supported the idea that androgen-ablation could mitigate tolerance to prostate cancer, creating a window during which tumor vaccination could prove successful (Cancer Cell 2005). At the current time, Dr. Drake is the co-director of the Multidisciplinary Prostate Cancer Clinic at Hopkins, where the combination of androgen-ablation and vaccination is being examined in a translational, pre-surgical trial. Using additional *in vivo* models, the Drake laboratory showed that the molecule LAG-3 is relatively over-expressed on non-functional T cells, and that LAG-3 blockade affects T cell function via both Treg dependent and Treg independent mechanisms (JCI 2007). More recently, the laboratory was able to show that blocking the immune checkpoints PD-1 and LAG-3 could prove synergistic in several *in vivo* cancer models. Ongoing work in the laboratory is focused on understanding the role of LAG-3 in regulatory T cell induction, as well as the regulation of immune checkpoint molecules and ligands in prostate and kidney cancer.



Bernard Escudier, MD

Dr. Escudier is a MD, trained in Paris. He got his MD in 1981 as a cardiologist, and moved to Gustave Roussy Institute in 1983, initially in the Intensive Care Unit, and then took the lead of the Immunotherapy Unit, mainly in charge of developing programs in renal cell carcinoma and in melanoma. His largest fields of interest are renal cell carcinoma, immunotherapy (cytokines, vaccine), and development of new strategies (antiangiogenic drugs, gene

therapy). He has been largely involved in the development of new targeted therapies for RCC, and has been the PI of many trials in the field of RCC, from phase I to phase III.

Dr. Escudier is the head of the French Group of Immunotherapy since 1992, and the chairman of the GU tumor board at Gustave Roussy Institute in Villejuif, France.

He is a member of ASCO, AACR, ESMO, and has been the chair of the GU Group of ESMO from 2008 to 2010, and is currently the ESMO faculty coordinator for the GU group. He has been leading the ESMO guidelines for kidney cancer in 2012 and 2014.

Continued on next page

BIOGRAPHIES

Dr. Escudier is also part of the steering committee of KCA, and has been in the scientific committee of the European kidney cancer symposium from the first meeting 8 years ago til now. Dr Escudier is also president of ARTuR, the French association for research for renal tumors.

Dr. Escudier is also leading the network CARARE, founded in 2013, devoted to rare kidney tumors in France.

He has published more than 370 papers in peer reviewed journals, mainly in the field of Renal Cancer.



Deborah Maskens

As co-founder of Kidney Cancer Canada (KCC), a national non-profit patient support and advocacy organization, Deb has worked tirelessly as a patient advocate to ensure equal access to high quality care for kidney cancer patients across Canada and around the world. As a long-time kidney cancer patient herself, Deb has been highly instrumental as a media spokesperson, government advocate, and peer supporter for fellow patients. Deb is a frequent spokesperson on matters pertaining to patient engagement, including in HTA processes such as pCODR (pan-Canadian Oncology Drug Review). She is currently co-leading the CanCertainty Coalition campaign for universal coverage of take-home cancer drugs across Canada on behalf of 35 cancer patient organizations.

Internationally, Deb is currently the Vice Chair of the International Kidney Cancer Coalition (IKCC) based in Amsterdam and an active contributor in the HTAi PCISG on matters relating to patient and public involvement in HTA.

Most recently she has been awarded the Canadian Governor General's Meritorious Service Medal, Canada's highest award for her dedication and professionalism in volunteer service.

BIOGRAPHIES



Ramaprasad Srinivasan, MD, PhD

Dr. Srinivasan is the Head of the Molecular Cancer Therapeutics Section of the National Cancer Institute (NCI). He obtained his M.D. from the Bangalore Medical College in India and completed his Ph.D. in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC). He is a reviewer for several prestigious journals including Cancer Research, Clinical Cancer Research, Lancet Oncology and Cancer.



Dawn Stacey, RN, PhD

Dawn Stacey RN PhD holds a Research Chair in Knowledge Translation to Patients and is a Full Professor in the School of Nursing at the University of Ottawa. She is the Scientific Director of the Patient Decision Aids Research Group at the Ottawa Hospital Research Institute. Her research includes being the principal-investigator for the Cochrane Review of Patient Decision Aids, co-chair of the Steering Committee for the International Patient Decision Aid Standards Collaboration (IPDAS), and co-investigator for the Cochrane Review of Interventions to Improve the Adoption of Shared Decision Making. The focus of her research program on Knowledge Translation to Patients includes: a) patient decision aids; b) decision coaching; c) implementation of evidence into practice; d) telephone-based care, and e) interprofessional approaches to shared decision making. For more information visit her research program website <http://decisionaid.ohri.ca>.

NOTES

WE WOULD LIKE TO THANK OUR SPONSORS

PLATINUM



GOLD



BRONZE



CONTRIBUTOR



This meeting has been endorsed by the Canadian Urological Association (CUA), February 2016.



Canadian
Urological
Association

The *Voice of Urology in Canada*

cua.org